Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Reed SD, Li Y, Dakin HA, Becker F, Leal J, Gustavson SM, Kartman B, Wittbrodt E, Mentz RJ, Pagidipati NJ, Bethel MA, Gray AM, Holman RR, Hernandez AF

Diabetes care5 Dec 2019Cited by 7 (Europe PMC)

PMID31806653PMCIDPMC7210004DOI10.2337/dc19-0950PepBankPUB-31806653

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialOther
In patients with diabetes, total costs using English prices and including exenatide were higher with exenatide than placebo.
In plain wordsIn patients with diabetes, total costs using English prices and including exenatide were higher with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTotal costs using English prices
Study
n = 14,752
Comparator
Placebo
Analysis
Secondary
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Total cost
10,874 GBP
exenatide
Total cost
9204 GBP
placebo
Mean total cost difference
1670 GBP
higher with exenatide than placebo, English costs
Source sentences
Summary
With English costs applied, mean total costs, including exenatide costs, were £1,670 higher in the EQW group than the placebo group (£10,874 vs. £9,204; P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary analyses used English costs.
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665308
02HumanRandomized controlled trialOther
In patients with diabetes, exenatide reduced inpatient days versus placebo over average follow-up of 3.3 years.
In plain wordsIn patients with diabetes, exenatide reduced hospital days compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInpatient days
Study
n = 14,752
Comparator
Placebo
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Inpatient days
7.05 days
exenatide
Inpatient days
7.46 days
placebo
Relative rate ratio
0.91 ratio
inpatient days, exenatide versus placebo
Inpatient days difference
0.41 days
fewer with exenatide than placebo
Source sentences
Summary
Patients were followed for an average of 3.3 years, during which time those randomized to EQW experienced 0.41 fewer inpatient days (7.05 vs. 7.46 days; relative rate ratio 0.91; P = 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665301
03HumanRandomized controlled trialOther
In patients with diabetes, outpatient visit rates were similar with exenatide and placebo.
In plain wordsIn patients with diabetes, outpatient visit rates were similar with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeOutpatient visit rate
Study
n = 14,752
Comparator
Placebo
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Rates of outpatient medical visits were similar, as were total inpatient and outpatient costs.
1 context sentence(design, population, supporting numbers)
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665302
04HumanRandomized controlled trialOther
In patients with diabetes, total inpatient costs were similar with exenatide and placebo.
In plain wordsIn patients with diabetes, total hospital costs were similar with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTotal inpatient costs
Study
n = 14,752
Comparator
Placebo
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Rates of outpatient medical visits were similar, as were total inpatient and outpatient costs.
1 context sentence(design, population, supporting numbers)
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665303
05HumanRandomized controlled trialOther
In patients with diabetes, total outpatient costs were similar with exenatide and placebo.
In plain wordsIn patients with diabetes, outpatient costs were similar with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTotal outpatient costs
Study
n = 14,752
Comparator
Placebo
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Rates of outpatient medical visits were similar, as were total inpatient and outpatient costs.
1 context sentence(design, population, supporting numbers)
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665304
06HumanRandomized controlled trialOther
In patients with diabetes, exenatide reduced costs of nonstudy diabetes medications compared with placebo.
In plain wordsIn patients with diabetes, exenatide reduced costs of other diabetes medicines compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNonstudy diabetes medication costs
Study
n = 14,752
Comparator
Placebo
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Cost reduction
≈ 1600 USD
exenatide versus placebo, nonstudy diabetes medications
Source sentences
Summary
Mean costs for nonstudy diabetes medications over the study period were ∼$1,600 lower with EQW than with placebo (P = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665305
07HumanRandomized controlled trialOther
In patients with diabetes, total costs excluding study medication were lower with exenatide than placebo.
In plain wordsIn patients with diabetes, total costs excluding study medication were lower with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal costs excluding study medication
Study
n = 14,752
Comparator
Placebo
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Total cost
28,907 USD
exenatide, excluding study drug
Total cost
30,914 USD
placebo, excluding study drug
Source sentences
Summary
Total within-study costs, excluding study medication, were lower in the EQW arm than in the placebo arm ($28,907 vs. $30,914; P ≤ 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665306
08HumanRandomized controlled trialOther
In patients with diabetes, total costs including estimated exenatide costs were higher with exenatide than placebo.
In plain wordsIn patients with diabetes, total costs including exenatide were higher with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTotal costs including estimated exenatide cost
Study
n = 14,752
Comparator
Placebo
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Total cost
42,697 USD
exenatide, including study drug
Total cost
30,914 USD
placebo
Source sentences
Summary
When including the estimated cost of EQW, total mean costs were significantly higher in the EQW group than in the placebo group ($42,697 vs. $30,914; P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665307
09HumanRandomized controlled trialOther
In patients with diabetes, EQ-5D health utilities did not differ significantly between exenatide and placebo over time.
In plain wordsIn patients with diabetes, measured health-related quality of life did not differ significantly between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeEQ-5D health utilities
Study
n = 14,752
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated
Source sentences
Summary
There were no significant differences in EQ-5D health utilities between arms over time.
1 context sentence(design, population, supporting numbers)
Summary · context
To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Report a problemFND-3180665309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

AstraZenecan = 14,75218 Jun 2010 to 24 Apr 2017

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 8 Aug 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.